Tradestie Institutional Equity Comparison Engine

ARGX vs MRNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ARGX Overall Edge

ARGX Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to argenx SE American Depositary Shares (ARGX) driven by superior Growth & Margin, Options & Structure while MRNA counters with relative strength in Valuation, Momentum & Technical. Fundamentally, ARGX trades at 27.8x Forward P/E with 31.9% operating margin (+52.1% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, ARGX sits in UNCLASSIFIED (33rd %ile IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
ARGX 27.8x vs MRNA 23.0x Fwd P/E
Growth & Margin Winner ARGX
Op Margin 31.9% vs -80.8% ยท YoY +52.1% vs +29.2%
Momentum & Technical Winner MRNA
1Y +1.2% vs +706.5% ยท 52W Pos 64% vs 67%
Options & Structure Winner ARGX
UNCLASSIFIED (33rd %ile IV) vs CONSOLIDATION (52nd %ile IV)
ARGX NASDAQ
argenx SE American Depositary Shares
Biological Products, (No Diagnostic Substances)
$925.70
-1.73% 1D
Market Cap $59.3B
1M Return +5.7%
1Y Return +1.21%
Forward P/E 27.8x
Unified AI Score
49.6 / 100 HOLD
Tech 38.0 Fund 47.0 Flow 50.0 Mom 60.0
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ARGX +1.21% MRNA +706.45% Spread: +705.24 pp (MRNA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ARGX TTM Op. Margin: 31.9% MRNA TTM Op. Margin: -80.8%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ARGX vs MRNA. Trailing 12-month operating profitability (ARGX 31.9% vs MRNA -80.8%) and valuation multiples (ARGX 27.8x vs MRNA 23.0x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ARGX (6) vs MRNA (4)
Institutional Metric ARGX MRNA Criterion Row Winner
Market Capitalization Scale $59.3B $80.7B Larger Scale MRNA
Trailing P/E Ratio Valuation 32.6x 23.0x Lower Multiple MRNA
Forward P/E Ratio Valuation 27.8x 23.0x Lower Multiple MRNA
Revenue Growth (YoY) Growth +52.1% +29.2% Higher Growth ARGX
Operating Margin (TTM) Profitability 31.9% -80.8% Higher Margin ARGX
Net Profit Margin Profitability 31.7% -110.5% Higher Margin ARGX
Return on Equity (ROE) Capital Efficiency 23.6% -34.5% Higher ROE ARGX
52-Week Range Position Momentum 64% ($662โ€“$1,073) 67% ($22โ€“$281) Stronger Trend MRNA
Beta / 30D Volatility Risk Regime 0.56ฮฒ ยท 31% Vol 2.23ฮฒ ยท 78% Vol Lower Realized Risk ARGX
Unified Institutional Score Composite Signal 49.6 / 100 (HOLD) 40.3 / 100 (SELL) Higher Composite ARGX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ARGX vs MRNA Buy Guide
ARGX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 33rd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ARGX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ARGX nor MRNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.